{"a":[{"_":"After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?","$":{"href":"/biotech/after-2-undisclosed-gene-therapy-deaths-can-china-iit-alternative-regulatory-path-still-be","hreflang":"en"}}]}
RegulatoryGene therapies (unspecified)Negative
AI Analysis
Summary
Two undisclosed patient deaths from severe immune reactions to high-dose viral vector gene therapies have raised international concerns about systemic gaps in oversight and transparency within China's IIT regulatory framework.
Outcome Details
Two patient deaths involving severe immune reactions to high-dose viral vector-delivered gene therapies with lack of disclosure
Importance:8/10
Sentiment:
-0.90
gene therapypatient safetyregulatory oversightChinaadverse eventstransparencyimmune reaction
Read the original article
Published by FierceBiotech on August 14, 2026 11:17 AM